Conditions: Hepatitis C, Chronic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 75
Healthy volunteers: no

Brief summary:
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients. Both treatment-naïve patients and patients previously treated with peginterferon and ribavirin were included. In addition, the effect of study medication was examined in a group of patients with liver cirrhosis.

Detailed description:

Arms:
arm 1: multiple rising doses arm 2: multiple rising doses arm 3: None

Interventions: intervention 1: BI 207127 NA intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: